Yahoo Finance

Virion Therapeutics Reports Positive Clinical Data with VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure, at APASL 2025 Global Liver Meeting

Safety, immunogenicity, and anti-HBV activity, presented in chronically HBV-infected patients following a single, prime-only, or a prime and boost, intramuscular injection of VRON-0200 Over 7,680 ...
Yahoo Finance

Virion Therapeutics Reports Progress Towards HBV Functional Cure with Continued HBsAg Declines, Without Rebound, Up to Two Plus Years, After a Single VRON-0200 Dose, From its ...

VRON-0200 was safe and well tolerated, with no serious treatment-related adverse events, treatment discontinuations, or treatment-related clinical laboratory abnormalities reported At end of study ...
Morningstar%2c Inc.

Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study ...

Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026 Virion ...
irblog.prnewswire.com

Virion Therapeutics, LLC Raises $5 Million to Develop Checkpoint Inhibitor Powered Vaccine Therapies for Treatment of Virally Induced Infectious Diseases & Cancers

PHILADELPHIA, Sept. 26, 2018 /PRNewswire/ -- A new Philadelphia-based start-up, Virion Therapeutics, LLC spun out of The Wistar Institute, will work to advance innovative, immune-based therapies for ...
irblog.prnewswire.com

Center for Breakthrough Medicines and Virion Therapeutics Announce Strategic Partnership to Manufacture Virion's Proprietary CD8+ T cell-based Clinical Development Programs for ...

"Virion is working to revolutionize the immunotherapy treatment landscape, and we are honored to partner with them on this bold mission as we share a common goal – to create a future free of cancer ...
MarketWatch

Virion Therapeutics Reports Progress Towards HBV Functional Cure with Sustained and Continued HBsAg Declines up to One Year After a Single VRON-0200 Dose From its Phase 1b ...

-- VRON-0200 was safe and well tolerated, with no serious treatment-related adverse events, treatment discontinuations, or treatment-related clinical laboratory abnormalities reported -- In the ...
Nasdaq

Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic hepatitis B study: now enrolling, with goal of a ...

PHILADELPHIA, Oct. 12, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and Ocean Biomedical, Inc. (NASDAQ: OCEA), a ...
Mena FN

Virion Therapeutics Reports New Data From Two Clinical Presentations At EASL 2025, Including Rapid And Profound Hepatitis B Surface Antigen Declines With The First VRON-0200 ...

.Over 8,295 and 821 safety days reported in VRON-0200 alone (n=27), and VRON-0200 combination treated patients (n=7), respectively; VRON-0200 was well tolerated, with no serious treatment-related ...
Hosted on MSN

Virion Therapeutics to Present New Chronic Hepatitis B Data at AASLD Liver Meeting

PHILADELPHIA, PA — Virion Therapeutics, LLC announced that new clinical data from its VRON-0200 program for chronic Hepatitis B virus (HBV) infection will be featured in an oral presentation at the ...
markets.financialcontent

Virion Therapeutics Reports Progress Towards HBV Functional Cure with Continued HBsAg Declines, Without Rebound, Up to Two Plus Years, After a Single VRON-0200 Dose, From its ...

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Professor Grace Wong, M.D., from the Chinese ...
Morningstar%2c Inc.

Virion Therapeutics Reports Progress Towards HBV Functional Cure with Continued HBsAg Declines, Without Rebound, Up to Two Plus Years, After a Single VRON-0200 Dose, From its ...

Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at the EASL Congress 2026 (The ...